BioStock: Pila Pharma takes XEN-D0501 into pain management

After focusing solely on diabetes as a development track for candidate XEN-D0501, Pila Pharma is now taking the next step of its journey filing an application for Orphan Drug Designation in the U.S. If this is approved, it will allow the company to expand its pipeline by adding a new indication. BioStock contacted CEO Dorte X. Gram to find out more about the venture and first quarter of the year.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/04/pila-pharma-takes-xen-d0501-into-pain-management/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se